Programmed death ligands 1 and 2 (PD-L1 and PD-L2) interact with PD-1 to reduce T-cell receptor signal transduction and downregulate T-cell activation, proliferation, and T-cell-mediated anti-tumor response [11–13]. Here, CD274 is linked to neoplasm.